Search filters
Update Reimbursement Scheme Forxiga® 10mg and Xigduo® 5mg

Update Reimbursement Scheme Forxiga® 10mg and Xigduo® 5mg

13/10/2023

TBR Nederland hereby informs you that from now on the conditions regarding the Reimbursement Scheme Forxiga® 10mg and Xigduo® 5mg...

Reimbursement Scheme Adhesa®

Reimbursement Scheme Adhesa®

08/09/2023

The health insurer does not fully reimburse Adhesa® 5 mg. The producer of this medicine has therefore asked TBR Nederland to...

Update Reimbursement Scheme Adempas®

Update Reimbursement Scheme Adempas®

06/09/2023

As off May 31st 2023, the reimbursement for Adempas® 0.5 mg and 1.0 mg is now also indicated for the treatment of PAH in pediatric...

Reimbursement Scheme Jardiance® - Chronic Kidney Disease

Reimbursement Scheme Jardiance® - Chronic Kidney Disease

20/07/2023

Arrangement for reimbursement by TerugBetaalRegeling Jardiance® (empagliflozin) 10 mg for patients with chronic kidney disease...

Update Reimbursement Scheme Forxiga® - HFpEF

Update Reimbursement Scheme Forxiga® - HFpEF

06/07/2023

TerugBetaalRegeling Forxiga® (dapagliflozin) 10 mg for patients with symptomatic chronic heart failure with a LVEF ≥ 40% (HFmrEF &...

You are currently offline. Some pages or content may fail to load.